Member Info for Hikikomori

It’s a fair comment MrsI

investing in a company doesn’t require you to just be in just that one, though clearly some here are arguably way over exposed. Yes, that may eventually provide them a huge return, but the opportunity loss being tied up here with no news to drive the SP forward is huge.

I skimmed off a third of my holding in September at just shy of £16 and, whilst accepting it was very fortunate timing, I am very glad I did. That left me a free hit on my remaining shares and the part I sold has been generating a not insignificant return elsewhere.

Given the recent board actions/inactions, I will be looking to trim my position further, at a price target lower than I had originally intended, if and when the SP recovers sufficiently.

Does that mean I am not allowed an opinion or that I’m not a supporter of the company - absolutely not.

It’s not a presentation leak, it’s been on the website in plain view for 2 weeks.

Not even allowed a week of price recovery after a massive recent sell off. Cheers Vlad

Peter,

If you withdraw any cash from your cash isa it will lose its tax wrapper status, however, a transfer to another broker is considered a transfer and not a withdrawal.

It will remain inside the tax free wrapper and will not impact on this years ISA allowance, assuming the money within it was already inside it before April 5th and not deposited this tax year.

Personally I would move from HL if I were you, their fees are ridiculous and the platform is antiquated.

Currently, the only positives they have going for them is a fee free junior ISA and the ability to talk to someone on the phone, beyond that they rely on legacy and brand recognition to keep and attract new customers.

Not sure how correlated Hemo is to the wider stock market, but risky assets are often quickest to be sold off. This share should be a small part of a much wider portfolio, not a balls deep holding. With potential good news coming soon, you’d be brave to sell this now unless you are very overweight here.

As has been the recent trend, I expect to see some late buying here before markets close, with people perhaps hoping for a Monday RNS.

Enjoy the weekend and let’s see what the world looks like on Monday.

T212 is absolutely fine for high liquidity, smaller spread investments like popular index funds or large cap stocks. For shares like Hemo with the bid/ask spread routinely at 5-10% I would always want to use a broker who provides an actual quote in real time before you complete the transaction. For that reason I personally wouldn’t use Freetrade either for any trades on Hemo.

T212 limit the number of shares you can hold in some shares, generally smaller companies and those they consider to be risky, volatile, or have low liquidity. You will almost certainly also have a limit set to your general investment account with them, even if it doesn’t appear to be the case.

I have a 212 ISA, but use a different ISA provider to hold Hemo

Pumpky is on the record as having traded the share regularly, he doesn’t hide it, so I don’t have any problem with it.

Whilst he is a trader, he is primarily a wind up merchant, and he isn’t likely to stop whilst many on here constantly take the bait.

He isn’t affecting the share price one way or another, so I don’t know why people get worked up about his comments.

Just like last time, I imagine you won’t get the buyer doing a TR-1 after getting the heavily discounted shares from Eric, as they will almost certainly have been forward sold at a profit, and as a further kick in the teeth to shareholders, they have bagged the warrants on top ( also for below the market price at the time of the deal).

Shareholders are being absolutely mugged here, and given the companies links to Ron Bauer, why am I not surprised…

JRDC,

I don’t believe the trial allows patients to have a second dose if they relapse. It’s once and done as I understand it.

It may be months before paediatric testing actually begins, but I believe the FDA have until sometime around the end of next week to raise an objection.

Not sure why you criticise Crunch, Micky has just stated something factual on this occasion.

Most of the stuff that ends up written here is just complete conjecture, the vast majority of which never comes to pass.

Maybe Micky just wanted to vent his frustration at how his investment has performed, which seems fair enough to me.

You missed one off your list rooster

>100 million shares issued

That level of dilution will tend to negatively impact the SP

Mr India’s constant glazing of Kingping has undoubtedly left him lubricated enough to feature in one of diddy’s freak off’s

We either need positive news on the outcome of the first patient, or news that we are funded for more than 10 minutes. Preferably both.

Mice video link

https://youtu.be/GBkT19uH2RQ?si=XP4YpTPAUlRoQOMH

I think I recall Hemo said they would be applying for an orphan drug designation for their CAR-T treatment. If designated as such, one of the benefits of orphan status is the ability to speed up trials.

In the second paragraph of the RNS pumpky

No, it’s only listed on the LSE main market.

Costs to develop this will hopefully be limited to some lentivirus and some staffing resource for the time being. There will be a likely cost to licence the IP from Kure if together we are successful in delivering an effective product, but I suspect that’s a bit away yet.

Still, it’s another positive development.